Description
FOLFOXIRI is an intensive chemotherapy regimen that combines all three active cytotoxic agents used in CRC: 5-FU/Leucovorin, Oxaliplatin, and Irinotecan. This "triplet" chemotherapy approach was pioneered by Italian researchers and offers higher response rates than doublet regimens (FOLFOX or FOLFIRI). It is particularly valuable for patients with initially unresectable liver metastases where tumor shrinkage could enable curative surgery (conversion therapy). However, FOLFOXIRI carries more toxicity and is typically reserved for fit patients who can tolerate the increased intensity.
Drugs in this Regimen
Mechanism of Action
Combines three complementary mechanisms: Oxaliplatin (platinum cross-links), Irinotecan (topoisomerase I inhibition), and 5-FU/Leucovorin (thymidylate synthase inhibition). The triple attack on cancer cell DNA through different pathways maximizes cell kill and reduces resistance.
Administration
14-day cycle
Day 1: Irinotecan 165mg/m² IV over 60 min + Oxaliplatin 85mg/m² IV over 2 hours + Leucovorin 200mg/m² IV over 2 hours, then 5-FU 3200mg/m² IV continuous infusion over 48 hours. Repeated every 14 days for up to 12 cycles.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.